In addition, although some c-Abl inhibitors are widely used in the treatment of chronic myelocytic leukemia, the potential risk that they pose for causing serious systemic adverse effects has been reported (Arora and Scholar, 2005). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.